近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Li, C.#, Zhan, W.#, Yang, Z.#, Tu, C.#, Hu, G.#, Zhang, X., Song, W., Du, S., Zhu, Y., Huang, K., Kong, Y., Zhang, M., Mao, Q., Gu, X., Zhang, Y., Xie, Y., Deng, Q., Song, Y., Chen, Z., Lu, L., Jiang, S., Wu, Y.*, Sun, L.*, Ying, T.* Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell, 185, 1–13, 2022
Wang, C.#, Hong, J.#*, Yang, Z.#, Zhou, X., Yang, Y., Kong, Y., Chen, B., Wu, H., Qian, B. Z., Dimitrov, D. S., Zhou, X., Wu, Y.*, Ying, T.* Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. Small Methods, 6(2), e2100966, 2021
Jin, Y. J., Yu, D., Tian, X. L., Li, H. X., Zhou, X. C., Kong, Y., Zhang, W., Zhang, L., Lei, C., Yang, Z. L., Tu, C., Wu, Y. L., Ying, T.* A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms. Acta Pharmacol Sin. 43(4):954-962, 2021
Li, C.#, Tian, X.#, Jia, X.#, Wan, J., Lu, L., Jiang, S., Lan, F., Lu, Y.*, Wu, Y.*, Ying, T.* The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Signal Transduct Target Ther, 6(1), 132, 2021
Yang, Z.#*, Wang, Y.#, Jin, Y.#, Zhu, Y.#, Wu, Y.#, Li, C., Kong, Y., Song, W., Tian, X., Zhan, W., Huang, A., Zhou, S., Xia, S., Tian, X., Peng, C., Chen, C., Shi, Y., Hu, G., Du, S., Wang, Y., Xie, Y., Jiang, S., Lu, L., Sun, L., Song, Y.*, Ying, T.* A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Signal Transduct Target Ther, 6(1), 378, 2021
Wu, Y.*, Li, C., Xia, S., Tian, X., Kong, Y., Wang, Z., Gu, C., Zhang, R., Tu, C., Xie, Y., Yang, Z., Lu, L., Jiang, S., Ying, T.* Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host Microbe. 27(6):891-898, 2020
Tian, X#., Li, C.#, Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y.*, Ying, T.* Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect, 9(1), 382-385, 2020
Hu D.#, Zhu Z.#, Li S.#, Deng Y.#, Wu Y., Zhang N., Puri V., Wang C., Zou P., Lei C., Tian X., Wang Y., Zhao Q., Li W., Prabakaran P., Feng Y., Cardosa J., Qin C., Zhou X.*, Dimitrov D.S.*, Ying T.* A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. PLoS Pathog. 15(6):e1007836, 2019
Wu Y.#, Xue J.#, Wang C., Li W., Wang L., Chen W., Prabakaran P., Kong D., Jin Y., Hu D., Wang Y., Lei C., Yu D., Tu C., Bardhi A., Sidorov I., Ma L., Goldstein H., Qin C., Lu L., Jiang S., Dimitrov D.S., Ying T.* Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. J Virol. 93(20). pii: e01077-19, 2019
Yu, F., Song, H., Wu, Y., Chang, S.Y., Wang, L., Li, W., Hong, B., Xia, S., Wang, C., Khurana, S., Feng, Y., Wang, Y., Sun, Z., He, B., Hou, D., Manischewitz, J., King, L.R., Song, Y., Min, J.Y., Golding, H., Ji, X., Lu, L., Jiang, S., Dimitrov, D.S., Ying, T.* A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host Microbe. 22:1-13, 2017.
京公网安备 11010802027423号